Skip to main content
Premium Trial:

Request an Annual Quote

Two Banks Upgrade Affy Stock, Shares Up 7 Percent on IP-infringement Verdict

NEW YORK (GenomeWeb News) – A pair of investment banks today upgraded Affymetrix’s stock one day after a court found its principal rival Illumina guilty of infringing five of its patents.
 
News of the verdict, which forced Illumina to pay Affy $16.7 million in royalties for past sales, continued to buoy Affy’s shares, which were up 6.5 percent, or $1.70, at $28.31 in mid-afternoon trading today.
 
Robert Baird today upgraded Affmetrix’s stock to ‘Outperform’ from ‘Neutral,’ and Leerink Swan upgraded it to ‘Outperform’ from ‘Market Perform.’

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.